Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337867 | 0.77 | MAOB (0.59) | MAOBBCHEACHETSHR | |
| SCHEMBL265188 | 0.77 | MAOB (0.59) | MAOBBCHEACHETSHR | |
| SCHEMBL11007003 | 0.74 | PARP1 (0.34) | PARP1 | |
| SCHEMBL12473302 | 0.70 | CES1 (0.32) | MAOBBCHEACHE | |
| SCHEMBL9581005 | 0.67 | TRPA1 (0.38) | MAOB | |
| SCHEMBL4049275 | 0.67 | TSHR (0.36) | TSHR | |
| SCHEMBL7867026 | 0.66 | MAOB (0.37) | MAOBBCHEACHE | |
| SCHEMBL1232463 | 0.64 | MAOB (0.40) | MAOBBCHEACHE | |
| SCHEMBL4439955 | 0.62 | MAOB (0.33) | MAOBTSHRPARP1 | |
| SCHEMBL9016008 | 0.60 | SLC22A2 (0.39) | MAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7524590-B2 | Methods for storing holographic data and articles having enhanced data storage lifetime derived therefrom | GENERAL ELECTRIC COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20070127329-A1 | Methods for storing holographic data and articles having enhanced data storage lifetime derived therefrom | GENERAL ELECTRIC COMPANY (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | MAOB 254/4885BCHE 124/4885ACHE 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.